MRPL37 Antibody

What is MRPL37 and what cellular functions does it perform?

MRPL37, also known as Mitochondrial Ribosomal Protein L37, is a component of the mitochondrial large ribosomal subunit (mt-LSU). It plays a critical role in protein synthesis within the mitochondria, which is essential for the production of proteins involved in the electron transport chain and oxidative phosphorylation . MRPL37 has several alternative names in the literature, including L37mt, MRP-L37, L2mt, MRP-L2, and RPML2 . The protein has a calculated molecular weight of approximately 48 kDa and is primarily localized to the mitochondrion, where it contributes to the assembly and function of mitochondrial ribosomes . Understanding this protein's role is important for research into mitochondrial function, protein synthesis, and related disorders.

What applications are MRPL37 antibodies typically validated for?

MRPL37 antibodies have been validated for multiple applications in research settings. The most commonly validated applications include:

Researchers should note that optimal dilutions might vary depending on the specific antibody and experimental conditions. It is always recommended to perform a titration experiment to determine the optimal antibody concentration for your specific experimental setup .

What species reactivity do commercially available MRPL37 antibodies exhibit?

The species reactivity of MRPL37 antibodies varies depending on the specific antibody clone and manufacturer. Based on the search results, the following reactivity patterns have been observed:

• Human-only reactivity

• Human and mouse reactivity

• Broader reactivity including human, mouse, rat, and sometimes additional species such as cow, dog, guinea pig, horse, rabbit, bat, and monkey

When selecting an antibody for your research, it is crucial to verify that the antibody has been validated for your species of interest. Cross-species reactivity is determined by sequence homology in the epitope region targeted by the antibody . Some manufacturers note that while they predict cross-reactivity based on sequence homology, this might not be covered by their product guarantees unless specifically tested .

What is the recommended sample preparation for MRPL37 detection in Western blotting?

For optimal detection of MRPL37 in Western blotting applications, researchers should follow these methodological guidelines:

When troubleshooting, remember that sample-dependent results may occur, and it's advisable to check validation data galleries provided by manufacturers for specific applications .

How do post-translational modifications affect MRPL37 protein detection using antibodies?

MRPL37 undergoes several post-translational modifications (PTMs) that can significantly impact antibody detection. According to the search results, MRPL37 has multiple documented PTM sites :

When designing experiments with MRPL37 antibodies, researchers should consider:

• Epitope masking: If the antibody's epitope contains or is near PTM sites, modification at these sites could mask the epitope and prevent antibody binding. For example, antibodies targeting the region around K127 might show differential binding depending on whether this lysine is acetylated or ubiquitinated.

• Epitope selection: When choosing between different MRPL37 antibodies, consider whether the epitope regions (e.g., AA 100-200 , AA 240-320 , or N-terminal regions ) contain known PTM sites that might affect detection.

• Experimental conditions: Cell signaling, stress, or disease states might alter the PTM profile of MRPL37. Consider using phosphatase inhibitors, deacetylase inhibitors, or proteasome inhibitors as appropriate to preserve the native modification state.

• Validation approach: To assess the impact of PTMs on antibody detection, consider using samples with differential modification states or treating samples with enzymes that remove specific modifications before antibody detection.

Understanding the PTM landscape of MRPL37 is crucial for accurately interpreting experimental results, especially in comparative studies between different physiological or pathological conditions.

What are the optimal protocols for MRPL37 immunohistochemical detection?

For researchers conducting immunohistochemistry (IHC) studies with MRPL37 antibodies, the following methodological considerations are important:

• Sample preparation:

  • Fixation: Paraformaldehyde (PFA) fixation has been successfully used for MRPL37 detection in immunofluorescence applications .

  • Permeabilization: Triton X-100 permeabilization has been validated for cellular staining .

  • Embedding: Paraffin embedding is compatible with MRPL37 IHC detection .

• Antigen retrieval:

  • The recommended method is TE buffer pH 9.0, though citrate buffer pH 6.0 can be used as an alternative .

  • Optimization of antigen retrieval is crucial as MRPL37 is a mitochondrial protein that may require specific conditions to expose epitopes after fixation.

• Antibody dilution:

  • For IHC applications, a dilution range of 1:50-1:500 is typically recommended .

  • The optimal dilution should be determined empirically for each tissue type and experimental condition.

• Detection systems:

  • Both chromogenic and fluorescent detection systems have been validated for MRPL37 detection.

  • For immunofluorescence, successful staining has been reported in U-2 OS (human bone osteosarcoma epithelial cell line) using an antibody concentration of 4 μg/ml .

• Positive control tissues:

  • Human fallopian tube tissue has been validated as a positive control for MRPL37 IHC (using a 1/20 dilution) .

  • Human lymphoma tissue has also been used successfully for MRPL37 detection .

To achieve optimal staining, it is recommended to perform a titration experiment with different antibody concentrations and to include both positive and negative controls in each experiment to validate staining specificity.

How can researchers validate the specificity of MRPL37 antibodies?

Validating antibody specificity is crucial for ensuring reliable research outcomes. For MRPL37 antibodies, researchers should consider the following comprehensive validation approaches:

• Positive and negative control samples:

  • Use tissues with known MRPL37 expression as positive controls. Based on the search results, human heart tissue, mouse liver tissue, mouse ovary tissue, and mouse uterus tissue have been validated for MRPL37 detection .

  • Consider using MRPL37 knockout or knockdown models as negative controls when available.

• Western blot validation:

  • Confirm that the antibody detects a band of the expected molecular weight (approximately 48 kDa) .

  • Look for a single, clean band rather than multiple bands that might indicate cross-reactivity.

  • Perform peptide competition assays where the antibody is pre-incubated with the immunogen peptide before application to verify specific binding.

• Orthogonal method validation:

  • Compare protein expression results with mRNA expression data from RT-PCR or RNA-seq.

  • Use multiple antibodies targeting different epitopes of MRPL37 and compare the results.

  • Consider mass spectrometry validation of the detected protein band.

• Cross-reactivity assessment:

  • Test the antibody in samples from multiple species if cross-species reactivity is claimed.

  • Perform siRNA knockdown of MRPL37 and confirm reduction in antibody signal.

• Application-specific validation:

  • For IHC/ICC applications, compare staining patterns with known mitochondrial localization (MRPL37 should localize to mitochondria).

  • Perform co-localization studies with established mitochondrial markers.

Remember that antibodies purified using affinity chromatography with epitope-specific immunogens, as mentioned in the search results , typically offer higher specificity compared to crude serum antibodies.

What are the key considerations for troubleshooting inconsistent results with MRPL37 antibodies?

When facing inconsistent results with MRPL37 antibodies, researchers should systematically assess the following factors:

• Antibody selection and quality:

  • Verify that the antibody detects endogenous levels of the protein, as specified for some antibodies in the search results .

  • Consider testing multiple antibodies targeting different epitopes (e.g., N-terminal regions vs. internal domains like AA 240-320) .

  • Check antibody lot-to-lot variation by requesting validation data from manufacturers.

• Sample preparation issues:

  • For mitochondrial proteins like MRPL37, ensure proper sample handling to preserve mitochondrial integrity.

  • Evaluate whether different fixation protocols affect detection, especially in IHC/ICC applications.

  • Consider the impact of sample storage conditions on protein degradation.

• Technical protocol considerations:

  • Optimize blocking conditions to reduce background signal.

  • Adjust antibody concentration within the recommended range (e.g., 1:500-1:1000 for WB, 1:50-1:500 for IHC) .

  • Evaluate incubation times and temperatures for optimal signal-to-noise ratio.

  • For IHC, compare different antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0) .

• Expression and modification variables:

  • Consider whether experimental conditions might alter MRPL37 expression or its post-translational modification status.

  • Assess whether the protein's subcellular localization might change under different experimental conditions.

  • Verify that the epitope region is not affected by any of the known PTMs (methylation, acetylation, ubiquitination, phosphorylation) .

• Detection system optimization:

  • Compare different secondary antibodies or detection methods.

  • Evaluate signal amplification techniques for low-abundance samples.

  • Consider longer exposure times for weak signals, being mindful of background.

When troubleshooting, implement a systematic approach by changing one variable at a time and documenting all protocol modifications meticulously.

How does MRPL37 expression differ across tissue types and what implications does this have for research design?

Understanding the tissue-specific expression patterns of MRPL37 is essential for experimental design and interpretation. Based on the search results and general knowledge of mitochondrial ribosomal proteins:

• Validated expression in specific tissues:

  • MRPL37 has been successfully detected in human heart tissue, mouse liver tissue, mouse ovary tissue, and mouse uterus tissue via Western blotting .

  • IHC detection has been validated in human fallopian tube tissue and human lymphoma tissue .

• Expression pattern considerations:

  • As a mitochondrial ribosomal protein, MRPL37 expression generally correlates with tissues having high energy demands and mitochondrial content.

  • Expression levels may vary based on the metabolic state of the tissue and the energy requirements of specific cell types within the tissue.

• Experimental design implications:

  • When designing experiments, include appropriate positive control tissues based on validated expression data.

  • Consider using a panel of tissues to establish relative expression levels if studying MRPL37 in a comparative context.

  • For IHC studies, be aware that antigen retrieval methods might need to be optimized for different tissue types, with both TE buffer pH 9.0 and citrate buffer pH 6.0 being potential options .

• Research applications:

  • Differential expression across tissues might provide insights into tissue-specific roles of mitochondrial translation.

  • Changes in MRPL37 expression might correlate with mitochondrial dysfunction in disease states.

  • Tissue-specific expression patterns should inform sample selection when studying potential roles of MRPL37 in health and disease.

When designing experiments to assess MRPL37 expression, researchers should consider both the basal expression level in their tissue of interest and potential changes under experimental or pathological conditions.

What emerging technologies might enhance MRPL37 detection and functional analysis?

As research technologies continue to evolve, several emerging approaches may enhance our ability to detect and analyze MRPL37:

• Advanced imaging techniques:

  • Super-resolution microscopy can provide detailed localization of MRPL37 within mitochondrial substructures.

  • Live-cell imaging with tagged MRPL37 could reveal dynamic aspects of mitochondrial ribosome assembly and function.

  • Proximity labeling techniques (BioID, APEX) could identify novel interaction partners of MRPL37 within the mitochondrial translation machinery.

• Single-cell analysis:

  • Single-cell proteomics might reveal cell-to-cell variation in MRPL37 expression that is masked in bulk tissue analysis.

  • Integration of single-cell transcriptomics with proteomics could provide insights into the regulation of MRPL37 expression.

• CRISPR-based approaches:

  • CRISPR knock-in of epitope tags could facilitate detection without relying on antibodies.

  • CRISPR screening might identify genes that functionally interact with MRPL37 in mitochondrial translation.

• Structural biology:

  • Cryo-EM studies of mitochondrial ribosomes could provide detailed information about MRPL37's structural role.

  • Understanding structural details could inform the design of better antibodies targeting specific conformational epitopes.

These emerging technologies promise to enhance our understanding of MRPL37's role in mitochondrial function and potentially reveal new aspects of its biology that are not accessible with current antibody-based detection methods.

How should researchers approach experimental design when studying MRPL37 in disease models?

When investigating MRPL37 in disease models, researchers should consider these methodological approaches: